Gyre Therapeutics, Inc.
NASDAQ:GYREBiotechnology
+$0.00 today
- Market cap
- $475.02M
- Beta
- 4.92
- P/E (TTM)
- -88.3
- EPS (TTM)
- -$0.07
Volume 0.47M
Average 0.09M
GYRE Total Liabilities
Everything the company owes to creditors and other parties.
Gyre Therapeutics, Inc.NASDAQ: GYRE
Total Liabilities · Q1 FY2026 · quarter ended Mar 2026
Total liabilities broadly unchanged from a year ago
Total liabilities stood at $25.03M at the end of Q1 FY2026, down 1.8% from a year earlier and up 4.9% from the prior quarter. Over 3 fiscal years it compounded at +23.9% a year.
Context
- Total liabilities amounted to 15.4% of total assets at the end of Q1 FY2026, down 4.2 pp from a year earlier.
- Total liabilities increased in 1 of the last 3 fiscal years.
What to watch
Whether total liabilities keeps falling in the next quarterly balance sheet after a -1.8% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Liabilities history
USD · from the balance sheet
- Latest · FY2025
- 23.85M USD
- Year-over-year change
- -11.7%
- 4-year CAGR
- +13.1%
| Period | Period end | Total Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 23.85M | -11.7% |
| FY2024 | 2024-12-31 | 27M | -73.7% |
| FY2023 | 2023-12-31 | 102.59M | +718.4% |
| FY2022 | 2022-12-31 | 12.54M | -14.0% |
| FY2021 | 2021-12-31 | 14.57M | — |
Total Liabilities vs competitors
How GYRE compares with its peers on the latest reported figures
- Peers report in different currencies, so total liabilities is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of -1.8% is the 3rd highest of 4, against a peer median of +19.9%.
- Total liabilities amounts to 15.4% of total assets for GYRE, versus a peer median of 174.5%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $398.86M USD | +265.4% | +177.3% | 330.4% | |
| Mar 2026 | $146M USD | +19.9% | +39.7% | 926.4% | |
| Mar 2026 | $37.43M USD | -57.3% | +5.7% | 18.5% | |
| Mar 2026 | $25.03M USD | -1.8% | +23.9% | 15.4% | |
AGMBAgomAb Therapeutics N.V. American Depositary Shares | Sep 2025 | €18.7M EUR | — | — | 11.3% |
| Peer median (excluding GYRE) | — | +19.9% | +39.7% | 174.5% | |
Competitors are the stored peer set for GYRE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 44.35M | 25.18M | 33.51M | 11.81M | 37.07M |
| Short-term Investments | 2.5M | 0 | 0 | 14.86M | 15.36M |
| Net Receivables | 1.82M | 15.61M | 16.84M | 29.15M | 36.95M |
| Inventory | 0 | 6.12M | 4.28M | 6.34M | 10.17M |
| Other Current Assets | 2.81M | 2.37M | 1.05M | 1.44M | 2.83M |
| Total Current Assets | 51.48M | 49.65M | 57.22M | 64.79M | 102.37M |
| Property, Plant & Equipment (Net) | 3.71M | 18.38M | 23.78M | 25.7M | 24.73M |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 1.86M | 1.7M | 1.71M | 4.73M |
| Long-term Investments | 0 | 7.39M | 23.43M | 24.57M | 0 |
| Tax Assets | 0 | 0 | 4.7M | 5.62M | 6.87M |
| Other Non-current Assets | 472K | 7.48M | 5.72M | 3.03M | 27.43M |
| Total Non-current Assets | 4.19M | 35.1M | 59.32M | 60.62M | 63.76M |
| Total Assets | 55.66M | 84.75M | 116.54M | 125.41M | 166.13M |
| Account Payables | 6.42M | 122K | 355K | 108K | 124K |
| Short-term Debt | 1.98M | 0 | 0 | 0 | 0 |
| Tax Payables | 0 | 0 | 5.05M | 2.83M | 2.94M |
| Deferred Revenue | 230K | 0 | 79K | 156K | 111K |
| Other Current Liabilities | 4.07M | 4.86M | 648K | 5.7M | 2.67M |
| Total Current Liabilities | 14.17M | 12.24M | 20.05M | 19.52M | 18.29M |
| Long-term Debt | 0 | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 213K | 928K | 852K |
| Other Non-current Liabilities | 0 | 173K | 82.13M | 5.68M | 4.41M |
| Total Non-current Liabilities | 408K | 294K | 82.54M | 7.49M | 5.56M |
| Total Liabilities | 14.57M | 12.54M | 102.59M | 27M | 23.85M |
| Common Stock | 31K | 64K | 77K | 86K | 91 |
| Retained Earnings | (402.69M) | 10.06M | (85.54M) | (73.45M) | (68.43M) |
| Accumulated OCI | 40.23M | (392K) | 1.45M | 501K | 2.32M |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 90.91K |
| Minority Interest | 0 | 29.7M | 29.78M | 35.08M | 36.25M |
| Total Equity | 41.09M | 72.22M | 13.95M | 98.4M | 142.28M |
| Total Debt | 2.39M | 613K | 409K | 1.6M | 939K |
| Net Debt | (41.96M) | (24.56M) | (33.1M) | (10.22M) | (36.13M) |
Gyre Therapeutics, Inc.
NASDAQ:GYRE
Intrinsic Alpha fair value
Locked
Current Price
$4.34
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.